VictoryShares Pioneer Asset-Based Income ETF(ABI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABI VictoryShares Pioneer Asset-Based Income ETF

Post-Mkt 09-03 18:21:50 EDT

24.73

-0.02

-0.10%

盘后24.72

-0.01-0.04%

16:04 EDT

High24.78	Low24.73	Vol1.03K
Open24.75	D1 Closing24.76	Amplitude0.20%
Mkt Cap56.26M	Tradable Cap56.26M	Total Shares2.28M
T/O25.53K	T/O Rate0.05%	Tradable Shares2.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABI","market":"US","secType":"STK","nameCN":"VictoryShares Pioneer Asset-Based Income ETF","latestPrice":24.7311,"timestamp":1788465600000,"preClose":24.755,"halted":0,"volume":1031,"hourTrading":{"tag":"盘后","latestPrice":24.72,"preClose":24.7311,"latestTime":"16:04 EDT","volume":5,"amount":123.6222,"timestamp":1788465846717,"change":-0.0111,"changeRate":-0.000449,"amplitude":0.000449},"delay":0,"changeRate":-0.0009654615229245644,"floatShares":2275000,"shares":2275000,"eps":0,"marketStatus":"Post-Mkt","change":-0.0239,"latestTime":"09-03 18:21:50 EDT","open":24.75,"high":24.78,"low":24.7311,"amount":25532,"amplitude":0.001975,"askPrice":30.92,"askSize":200,"bidPrice":21.75,"bidSize":310,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788480000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":24.755,"sharesOutstanding":2275000,"nav":24.689813,"aum":56169295,"dividendRate":0.063721,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.72,"preClose":24.7311,"latestTime":"16:04 EDT","volume":5,"amount":123.6222,"timestamp":1788465846717,"change":-0.0111,"changeRate":-0.000449,"amplitude":0.000449},"volumeRatio":0.101106},"requestUrl":"/m/hq/s/ABI/tweets","defaultTab":"tweets","newsList":[{"id":"2662520874","title":"Octopus APAC Details Profitability Drive and ABI Termination Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2662520874","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662520874?lang=en_us&edition=fundamental","pubTime":"2026-08-25 01:32","pubTimestamp":1787592755,"startTime":"0","endTime":"0","summary":"GS Holdings Ltd. (Singapore) ( ($SG:43A) ) has provided an announcement. Octopus (APAC) Holdings laid out key priorities to turning its loss-making...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/octopus-apac-details-profitability-drive-and-abi-termination-response?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/octopus-apac-details-profitability-drive-and-abi-termination-response?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2896262040.SGD","LU0742534661.SGD","IE0034235188.USD","LU1868837300.USD","LU1894683264.USD","LU1868836914.USD","LU0061475181.USD","LU1804176565.USD","LU2471134952.CNY","STmain","ABI","BK4550","IE00B19Z3B42.SGD","LU2237443978.SGD","LU0942090050.USD","LU2237443895.HKD","LU0210536198.USD","LU2471134879.HKD","BK4127","LU2237438978.USD","IE0004091025.USD","LU2237443382.USD","LU1868836591.USD","LU2237443465.HKD","BK4552","BK4588","APAC","LU1144417596.USD","LU1791807156.HKD","LU2237443622.USD","LU2750360997.AUD","GSX","LU1894683348.USD","LU2750360641.GBP","LU1668664300.SGD","LU0096364046.USD","BK4504","LU0868494617.USD","LU1868836757.USD","LU0868494708.USD","LU0251131958.USD","IE00BSNM7G36.USD","BK4209","BK4533","LU0251142724.SGD","LU2471134523.USD","LU2237443549.SGD","IE00BFXG1179.USD","SG","LU0048573561.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651415534","title":"Aegon warns red tape is blocking pension investment spree","url":"https://stock-news.laohu8.com/highlight/detail?id=2651415534","media":"cityam","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651415534?lang=en_us&edition=fundamental","pubTime":"2026-07-16 13:00","pubTimestamp":1784178000,"startTime":"0","endTime":"0","summary":"One Mansion House signatory has raised concerns over regulatory barriers  Aegon has warned that regulation is holding back some of Britain’s top pension fund managers from pumping cash into the country’s start-ups and unlisted companies.The pension giant, which manages 160bn of assets in the UK alone, was one of 11 companies alongside Aviva and Legal & General to commit to investing five per cent of their assets in unlisted equities by 2030. However, Aegon has warned that regulatory hurdles could throw timelines into doubt as the City marks the three year anniversary of the agreement’s signing.“While we have made meaningful progress, we remain concerned about the timeline to the 2030 Mansion House Compact target,” Lorna Blyth, managing director, investment proposition at Aegon, told City AM.Providers said “managing appropriate fee structures remains problematic”, as certain models used in private capital markets are “financially unfeasible”.To protect savers from having their pension p","market":"us","thumbnail":"https://www.cityam.com/wp-content/uploads/2026/02/London-insurance-e1770395080662.jpg?w=824&h=463&crop=1","type":0,"news_type":0,"thumbnails":["https://www.cityam.com/wp-content/uploads/2026/02/London-insurance-e1770395080662.jpg?w=824&h=463&crop=1"],"rights":{"source":"cityam_highlight","url":"https://www.cityam.com/aegon-warns-red-tape-is-blocking-pension-investment-spree/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.cityam.com/aegon-warns-red-tape-is-blocking-pension-investment-spree/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"cityam_highlight","symbols":["ITDE","ABI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645489021","title":"MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2645489021","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645489021?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126000,"startTime":"0","endTime":"0","summary":"The IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with ASD A prespecified analysis in adolescents with moderate to severe baseline irritability (ABC-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315170/0/en/MapLight-Announces-Topline-Results-from-Phase-2-IRIS-Study-for-ML-004-in-Autism-Spectrum-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABI","ASD","SPB","BK4018","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637163903","title":"Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2637163903","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637163903?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:00","pubTimestamp":1779447600,"startTime":"0","endTime":"0","summary":"– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 –– Builds on completed Phase 1a study and ongoing development in HDV – SOUTH SAN FRANCISCO, Ca","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3300036/16259/en/Assembly-Biosciences-Announces-Expansion-of-ABI-6250-Clinical-Development-Into-Cholestatic-Liver-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSC","ABI","BK4588","HDV","BK4585","ASMB","PBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635723955","title":"Press Release: MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723955?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789100,"startTime":"0","endTime":"0","summary":"-- Enrollment completed in ML-007C-MA's Phase 2 ZEPHYR trial in. schizophrenia, with topline results expected by mid-August 2026. -- Last patient visit completed for ML-004's Phase 2 IRIS trial in autism. -- Enrollment ongoing in ML-007C-MA's Phase 2 VISTA trial in Alzheimer's. disease psychosis, with topline results expected in the second half of. -- Ended the quarter with $395.2 million in cash, cash equivalents and. investments, which is expected to fund operations through 2027. \"We are continuing to see strong momentum across our clinical portfolio, including completion of enrollment in the Phase 2 ZEPHYR and IRIS trials, \" said Chris Kroeger, co-Founder and Chief Executive Officer of the Company. \"With topline results from both studies expected by mid-August, continued advancement of our VISTA trial in Alzheimer's disease psychosis and progress across our early-stage pipeline, MapLight is entering an important inflection point in our mission to improve the lives of patients living","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADP","LU0957791311.USD","LU2404859741.USD","LU1868837136.USD","LU2023250330.USD","LU1803068979.SGD","MA","IE000WAW04H5.SGD","IE000MB6IJN5.SGD","LU1363072403.SGD","BK4106","LU0198837287.USD","LU1236620834.HKD","IE00B4JS1V06.HKD","LU0494093205.USD","LU1228905540.USD","LU0965509283.SGD","LU0094547139.USD","LU2756315664.SGD","SGXZ81514606.USD","LU1037948897.HKD","MPLT","ABI","LU0390134368.USD","LU0061474705.USD","IE00B1XK9C88.USD","LU0234572021.USD","LU0690374615.EUR","LU1718418525.SGD","LU2506951958.HKD","LU2896262040.SGD","BK4566","LU0965509101.SGD","IE00BFSS7M15.SGD","IE000SO60NU8.SGD","LU0868494617.USD","BK4227","LU1712237335.SGD","LU0170899867.USD","LU1236620750.USD","LU2361044865.SGD","LU0950375773.USD","SG9999000418.SGD","LU1989772840.SGD","LU0061474960.USD","LU0823421416.USD","IE00B775H168.HKD","LU2168564149.EUR","LU2552382132.HKD","LU0820561818.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635747413","title":"Press Release: Altria Holds 2026 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.06 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2635747413","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635747413?lang=en_us&edition=fundamental","pubTime":"2026-05-15 02:30","pubTimestamp":1778783400,"startTime":"0","endTime":"0","summary":"Altria Group, Inc.   held our 2026 Annual Meeting of Shareholders  today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer , addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com.Following today's Annual Meeting, Sal Mancuso succeeded Billy Gifford as Altria's CEO. At the end of 2025, Billy Gifford announced his decision to retire after more than 30 years of distinguished service with the Altria family of companies.\"Sal is immensely qualified to lead Altria, having served in numerous leadership positions during his more than 30-year career with us, including as Chief Financial Officer,\" said Billy Gifford. \"Altria has a bright future under his leadership.\". Our wholly owned subsidiaries include leading manufacturers of both combustible and smoke-free products. In combustibles, we own Philip Morris USA Inc. , the most profitable U.S. cigarette manufacturer, and John Middleton Co. , a leading U.S.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MST","BK4022","SG9999001440.SGD","BK4588","BK4232","LU1066051225.USD","BK4566","LU1116320901.HKD","BK4585","R","CEO","LU2381873111.SGD","LU1066051811.HKD","BK4075","LU1066051498.USD","MO","LU1066053197.SGD","HK0000819398.USD","LU0265550359.USD","LU0265550946.USD","ABI","LU1116320737.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629059620","title":"Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2629059620","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629059620?lang=en_us&edition=fundamental","pubTime":"2026-04-22 01:00","pubTimestamp":1776790800,"startTime":"0","endTime":"0","summary":"NEW YORK, April  21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in trans","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3278310/0/en/Royalty-Pharma-Launches-Global-Translational-Prize-to-Recognize-Breakthrough-Scientific-Innovation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621700007","title":"Assembly Biosciences Advances HSV-2 Drug ABI-1179 With Completion of Early-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621700007","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621700007?lang=en_us&edition=fundamental","pubTime":"2026-03-24 00:30","pubTimestamp":1774283439,"startTime":"0","endTime":"0","summary":"Assembly Biosciences Inc ($ASMB) announced an update on their ongoing clinical study. Assembly Biosciences Inc. (ASMB) is running a Phase 1a/1b tri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/assembly-biosciences-advances-hsv-2-drug-abi-1179-with-completion-of-early-stage-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/assembly-biosciences-advances-hsv-2-drug-abi-1179-with-completion-of-early-stage-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASMB","ABI","SSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0003},{"period":"1month","weight":-0.0036},{"period":"3month","weight":-0.0044},{"period":"6month","weight":-0.0112},{"period":"1year","weight":-0.0165},{"period":"ytd","weight":-0.0032}],"compareEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":0.0099},{"period":"3month","weight":0.0107},{"period":"6month","weight":0.138},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1221}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"VictoryShares Pioneer Asset-Based Income ETF","nameEN":"VictoryShares Pioneer Asset-Based Income ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VictoryShares Pioneer Asset-Based Income ETF(ABI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VictoryShares Pioneer Asset-Based Income ETF(ABI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VictoryShares Pioneer Asset-Based Income ETF,ABI,VictoryShares Pioneer Asset-Based Income ETF股票,VictoryShares Pioneer Asset-Based Income ETF股票老虎,VictoryShares Pioneer Asset-Based Income ETF股票老虎国际,VictoryShares Pioneer Asset-Based Income ETF行情,VictoryShares Pioneer Asset-Based Income ETF股票行情,VictoryShares Pioneer Asset-Based Income ETF股价,VictoryShares Pioneer Asset-Based Income ETF股市,VictoryShares Pioneer Asset-Based Income ETF股票价格,VictoryShares Pioneer Asset-Based Income ETF股票交易,VictoryShares Pioneer Asset-Based Income ETF股票购买,VictoryShares Pioneer Asset-Based Income ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VictoryShares Pioneer Asset-Based Income ETF(ABI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VictoryShares Pioneer Asset-Based Income ETF(ABI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}